Better Therapeutics, Inc. (BTTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Better Therapeutics, Inc. (BTTX) trades at $0.00 with AI Score 48/100 (Grade C). Better Therapeutics, Inc. (BTTX) is a biotechnology company focused on developing software-driven prescription digital therapeutics for cardiometabolic diseases. Market cap: $5,452, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for BTTX: BTTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BTTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BTTX: the 1 perspectives are evenly split.
How is this calculated? →Better Therapeutics, Inc. (BTTX) Healthcare & Pipeline Overview
Better Therapeutics, Inc. is a pioneer in software-driven prescription digital therapeutics, focusing on innovative solutions for managing cardiometabolic diseases, particularly diabetes, through its unique Nutritional Cognitive Behavioral Therapy platform.
What Is the Investment Thesis for BTTX?
Better Therapeutics, Inc. is positioned for growth in the burgeoning digital therapeutics market, which is expected to reach $13 billion by 2025. The company’s lead product, BT-001, is in advanced stages of development and targets the significant type 2 diabetes market, which affects over 34 million Americans. The integration of Nutritional Cognitive Behavioral Therapy into its PDTs offers a competitive edge, as it addresses behavioral aspects of disease management. Moreover, the ongoing development of BT-002 and BT-003 expands the company's therapeutic portfolio, catering to hypertension and hyperlipidemia, respectively. As healthcare increasingly shifts toward digital solutions, Better Therapeutics stands to benefit from favorable regulatory trends and growing acceptance of digital health interventions. However, investors may want to evaluate potential risks, including regulatory hurdles and market competition, as the company seeks to establish its products in a rapidly evolving landscape.
Based on FMP financials and quantitative analysis
BTTX Key Highlights
- Market Cap: $0.00B, indicating a current valuation reflecting early-stage development.
- Beta: 1.69, suggesting higher volatility compared to the market.
- Employee Count: 54, indicating a focused team dedicated to innovation in digital therapeutics.
- No Dividend Yield, reflecting reinvestment of resources into product development.
- Flagship Product: BT-001, targeting the large type 2 diabetes market.
Who Are BTTX's Competitors?
BTTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVCR Novocure | $17.70 | +2.92% | $2.05B | 55 |
| MDRX Veradigm Inc. | $5.09 | +1.90% | $865.28M | 50 |
| RMD ResMed Inc. | $220.60 | +5.23% | $32.00B | 95 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BTTX's Key Strengths?
- Innovative product pipeline targeting high-prevalence chronic diseases.
- Strong focus on software-driven therapeutic solutions.
- Experienced leadership team with a background in biotechnology and healthcare.
What Are BTTX's Weaknesses?
- Limited market presence as a relatively new company.
- Dependence on regulatory approvals for product commercialization.
- No current revenue stream, as products are still in development.
What Could Drive BTTX Stock Higher?
- Regulatory approval processes for BT-001 and other products in the pipeline.
- Development and clinical trials for BT-002 and BT-003.
- Potential partnerships with healthcare providers to enhance market access.
- Engagement with payers for reimbursement strategies.
- Expansion efforts into international markets.
What Are the Key Risks for BTTX?
- Financial-distress signal — its Altman Z-Score of -27.28 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory delays that could impact product launch timelines.
- Competition from both established and emerging digital therapeutics companies.
- Market acceptance of digital health solutions may take time.
- Dependence on successful clinical trial outcomes to validate product efficacy.
What Are the Growth Opportunities for BTTX?
- Growth opportunity 1: The U.S. digital therapeutics market is projected to reach $13 billion by 2025, driven by increasing healthcare costs and the demand for effective chronic disease management solutions. Better Therapeutics' focus on cardiometabolic diseases positions it to capture a significant share of this growing market, particularly with its innovative NCBT-based therapies.
- Growth opportunity 2: The rising prevalence of type 2 diabetes, affecting over 34 million Americans, presents a substantial opportunity for Better Therapeutics. With BT-001 targeting this demographic, the company can leverage partnerships with healthcare providers and payers to enhance patient access and adoption, potentially leading to substantial revenue growth.
- Growth opportunity 3: Expansion into international markets represents a key growth driver for Better Therapeutics. As digital health solutions gain traction globally, the company can explore partnerships and collaborations in regions with high diabetes and hypertension prevalence, further broadening its market reach.
- Growth opportunity 4: The increasing acceptance of digital health solutions by healthcare professionals and patients can enhance Better Therapeutics' market penetration. As healthcare systems prioritize value-based care, the efficacy of PDTs like BT-001 may lead to favorable reimbursement policies, facilitating wider adoption and usage.
- Growth opportunity 5: Ongoing advancements in technology, including artificial intelligence and machine learning, can enhance Better Therapeutics' product offerings. By integrating these technologies into its PDT platforms, the company can improve patient engagement and outcomes, thus differentiating itself in a competitive market.
What Opportunities Does BTTX Have?
- Rapid growth in the digital therapeutics market.
- Increasing prevalence of chronic diseases presents a large patient base.
- Potential for strategic partnerships to enhance market reach.
What Threats Does BTTX Face?
- Intense competition from established pharmaceutical and biotech companies.
- Regulatory challenges that could delay product launches.
- Market acceptance of digital therapeutics is still evolving.
What Are BTTX's Competitive Advantages?
- Innovative use of Nutritional Cognitive Behavioral Therapy sets it apart from traditional treatments.
- Focus on software-driven solutions aligns with the increasing trend toward digital health.
- Strong emphasis on research and development fosters continuous innovation.
- Potential for partnerships with healthcare providers enhances market credibility.
- Targeting high-prevalence chronic diseases provides a large addressable market.
What Does BTTX Do?
Founded in 2015 and headquartered in San Francisco, California, Better Therapeutics, Inc. specializes in the development of software-driven prescription digital therapeutics (PDTs) targeting cardiometabolic conditions. The company was established with the vision of leveraging technology to improve health outcomes in patients suffering from chronic diseases such as diabetes and heart disease. Better Therapeutics has made significant strides in creating its flagship product, BT-001, which utilizes Nutritional Cognitive Behavioral Therapy (NCBT) to help patients manage type 2 diabetes effectively. This innovative approach combines behavioral therapy with nutritional guidance, aiming to empower patients to make sustainable lifestyle changes. In addition to BT-001, the company is advancing its pipeline with BT-002, aimed at assisting patients with hypertension in controlling blood pressure, and BT-003, which focuses on optimizing cholesterol levels for individuals with hyperlipidemia. Better Therapeutics operates primarily in the U.S. market, where the demand for effective digital health solutions is rapidly growing, driven by the increasing prevalence of cardiometabolic diseases. The company's commitment to innovation and patient-centric solutions positions it uniquely in the biotechnology sector, addressing critical health challenges with scalable digital interventions.
What Products and Services Does BTTX Offer?
- Develop software-driven prescription digital therapeutics (PDTs) for chronic diseases.
- Focus on managing cardiometabolic conditions such as diabetes, hypertension, and hyperlipidemia.
- Utilize Nutritional Cognitive Behavioral Therapy (NCBT) in its digital therapeutics.
- Conduct research and development to innovate new therapeutic solutions.
- Engage with healthcare providers to promote digital health solutions.
- Aim to improve patient outcomes through behavioral and lifestyle interventions.
How Does BTTX Make Money?
- Generate revenue through the development and commercialization of prescription digital therapeutics.
- Potential partnerships with healthcare providers and payers for broader market access.
- Focus on subscription-based models for ongoing patient engagement and support.
- Leverage data analytics to enhance product offerings and patient outcomes.
- Seek regulatory approvals to ensure product viability and market entry.
What Industry Does BTTX Operate In?
The biotechnology industry, particularly in the healthcare sector, is witnessing a significant shift towards digital therapeutics, which are projected to grow rapidly as healthcare providers and patients increasingly embrace technology-driven solutions. With the global digital therapeutics market expected to expand at a CAGR of 20% through 2025, companies like Better Therapeutics are well-positioned to capitalize on this trend. The competitive landscape includes a mix of established pharmaceutical companies and innovative startups, all vying to develop effective digital solutions for chronic disease management. Better Therapeutics' focus on cardiometabolic conditions places it in a critical segment of the market, addressing the needs of millions affected by these diseases.
Who Are BTTX's Key Customers?
- Patients suffering from chronic diseases, particularly type 2 diabetes.
- Healthcare providers looking for innovative treatment options.
- Payers and insurance companies interested in cost-effective health solutions.
- Pharmaceutical companies seeking partnerships in digital health.
- Health systems aiming to improve patient management and outcomes.
Net buyingInsider Activity
The most recent 12 insider filings for Better Therapeutics, Inc. break down as 0 sales and 12 purchases. On net that is roughly 2.5M shares acquired (about $410K) — insiders putting money in tends to read as conviction.
FY2026 estForward Outlook
Wall Street analysts project Better Therapeutics, Inc. revenue of about $15.3M for fiscal 2026, with EPS near $-0.69.
F-Score 2/9Financial Health
Better Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.28 places it in the distress zone, a signal of elevated financial risk.
Better Therapeutics, Inc. (BTTX) Valuation Context
Valued at 5K, BTTX is classified as a micro-cap stock. Relative to its peer group, BTTX's quantitative score of 48/100 is below the peer average of 72/100.
Company Profile
Better Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO David Perry. BTTX has traded publicly since 2021.
BTTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative product pipeline targeting high-prevalence chronic diseases.
- Strong focus on software-driven therapeutic solutions.
- Experienced leadership team with a background in biotechnology and healthcare.
- Upcoming: Regulatory approval processes for BT-001 and other products in the pipeline.
Bear Case
- Limited market presence as a relatively new company.
- Dependence on regulatory approvals for product commercialization.
- No current revenue stream, as products are still in development.
- Potential: Regulatory delays that could impact product launch timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BTTX Latest News
No recent news available for BTTX.
BTTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BTTX.
Price Targets
Wall Street price target analysis for BTTX.
BTTX MoonshotScore
What does this score mean?
The MoonshotScore rates BTTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Perry
CEO
David Perry has extensive experience in the healthcare and biotechnology sectors, having held various leadership positions in both public and private companies. He has a strong track record in product development and commercialization, with a focus on innovative therapeutic solutions. Perry holds a degree in Biomedical Engineering and has been instrumental in guiding Better Therapeutics since its inception.
Track Record: Under David Perry's leadership, Better Therapeutics has developed its flagship product, BT-001, and expanded its pipeline with additional PDTs. He has successfully navigated the company through early-stage development, positioning it for future growth in the digital therapeutics market.
BTTX OTC Market Information
The OTC Other tier includes companies that do not meet the criteria for higher tiers like OTCQX or OTCQB. These companies may have limited liquidity and disclosure requirements, making them riskier investments compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight compared to companies listed on major exchanges.
- Potential for lower liquidity, leading to price volatility.
- Increased risk of fraud or misrepresentation in financial reporting.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Examine the competitive landscape and market positioning.
- Understand the regulatory environment for digital therapeutics.
- Evaluate the product pipeline and development timelines.
- Partnerships with reputable healthcare organizations.
- Transparency in communication and financial reporting.
- Positive feedback from clinical trials or pilot programs.
BTTX Healthcare Stock FAQ
What does Better Therapeutics, Inc. do?
Better Therapeutics, Inc. develops software-driven prescription digital therapeutics (PDTs) aimed at managing chronic diseases such as diabetes and hypertension. Their flagship product, BT-001, utilizes Nutritional Cognitive Behavioral Therapy to help patients manage type 2 diabetes. The company focuses on innovative, technology-based solutions to improve health outcomes for patients with cardiometabolic conditions.
How does Better Therapeutics, Inc. navigate regulatory approval processes?
Better Therapeutics, Inc. engages in a thorough regulatory strategy to ensure compliance with FDA guidelines for its digital therapeutics. The company conducts extensive clinical trials to demonstrate the efficacy and safety of its products, which is critical for obtaining necessary approvals. Their approach includes proactive communication with regulatory bodies to facilitate a smoother approval process.
What are the main risks for BTTX?
The primary risks for Better Therapeutics, Inc. include regulatory hurdles that could delay product launches, as well as competition from established companies in the digital therapeutics space. Additionally, market acceptance of their digital health solutions may take time, and the company is dependent on successful clinical trial outcomes to validate the efficacy of its products. These factors could impact the company's growth trajectory and market positioning.
What are the key factors to evaluate for BTTX?
Better Therapeutics, Inc. (BTTX) holds an AI score of 48/100 (low). Not financial advice.
How frequently does BTTX data refresh on this page?
BTTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BTTX's recent stock price performance?
Better Therapeutics, Inc. (BTTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting high-prevalence chronic diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BTTX overvalued or undervalued right now?
Valuing Better Therapeutics, Inc. (BTTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BTTX?
Before investing in Better Therapeutics, Inc. (BTTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company is in the early stages of development, and financial metrics are limited.